Skip to Main ContentSkip to FooterSkip to Search
Main menu
  1. Home
  2.  » 
  3. Expert Content
  4.  » 
  5. Development & Bioavailability
  6.  » Softgel Formulation Enables Oral Delivery of Testosterone
Icon of a document with a magnifying glass

Softgel Formulation Enables Oral Delivery of Testosterone

Summary: Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that has developed and commercialized JATENZO® softgel capsules, the first FDA-approved oral testosterone undecanoate for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Clarus partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. In March 2019, the U.S. FDA approved JATENZO (testosterone undecanoate), a proprietary formulation designed to overcome the challenges associated with oral testosterone dosing using softgel capsules.​

Click here to download case study.